CN100479819C - Composition comprising itraconazole for oral administration - Google Patents

Composition comprising itraconazole for oral administration Download PDF

Info

Publication number
CN100479819C
CN100479819C CNB2006100651366A CN200610065136A CN100479819C CN 100479819 C CN100479819 C CN 100479819C CN B2006100651366 A CNB2006100651366 A CN B2006100651366A CN 200610065136 A CN200610065136 A CN 200610065136A CN 100479819 C CN100479819 C CN 100479819C
Authority
CN
China
Prior art keywords
itraconazole
solid dispersion
orally administered
administered composition
weight portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006100651366A
Other languages
Chinese (zh)
Other versions
CN1853634A (en
Inventor
郑炯峻
文炳官
李祐荣
朴俊锡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sam Chun Dang Pharm Co Ltd
Original Assignee
Sam Chun Dang Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sam Chun Dang Pharm Co Ltd filed Critical Sam Chun Dang Pharm Co Ltd
Publication of CN1853634A publication Critical patent/CN1853634A/en
Application granted granted Critical
Publication of CN100479819C publication Critical patent/CN100479819C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses an intake composition with Yiqu-pyrazole, which comprises the following parts: 40-69.9 wt% solid dispersion, 0.1-30 wt% penetrating inducer and 0.1-30 wt% disintegration agent, wherein the solid dispersion is prepared by dispersing 1 wt% Yiqu-pyrazole in the 0.1-10wt% methyl hydroxypropylcellulose to mix with 0.01-5wt% absorbing accelerating agent in the composition at amorphous pattern.

Description

Be used for compositions oral administration, that contain itraconazole
The mutual reference of related application
The application requires the priority of the korean patent application No.10-2005-0022312 that submits on March 17th, 2005, and this description is included in described application by reference mode hereby in, so that it is as complete in this manual proposition.
Invention field
The present invention relates to a kind of Orally administered composition, described compositions contains the solid dispersion of 40~69.9wt% (percentage by weight), the infiltration derivant of 0.1~30wt% and the disintegrating agent (disintegrant) of 0.1~30wt%, wherein, described solid dispersion is dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1~10 weight portion and 0.01~5 weight portion and prepares with amorphism.
Background technology
Itraconazole, be called again (±)-suitable-4-that (((((2-(2 for 4-for 4-for 4-, the 4-Dichlorobenzene base)-2-(1H-1,2,4-triazol-1-yl methyl)-1,3-dioxolanes-4-yl) phenyl methoxyl group))-and the 1-piperazinyl)-2,4-dihydro-2-(1-methyl-propyl)-3H-1,2,4-triazole-3-ketone, having known it is a kind of fungicidal agents with antifungal broad spectrum activity, particularly a kind of safe and effective medicine for the treatment of dermatomycosis.Yet although itraconazole has effective Fungicidally active, it is a kind of insoluble drugs, and its water solublity and pKa value are all lower, is respectively below the 1 μ g/ml with 3.7, so promptly be ionized under very low pH.Therefore, there is the low-down problem of its bioavailability in itraconazole when oral administration.
For the water solublity that improves itraconazole improving its bioavailability, WO 85/002767 and US4,764,604 disclose the clathrate (includedcomplex) of a kind of itraconazole and cyclodextrin, but all fail to improve the water solublity of itraconazole.In addition, US 5,504,105 disclose a kind of oral Pharmaceutical composition, this pharmaceutical composition is characterised in that active component is dispersed in hydrogenated vegetable oil, medium chain triglycerides, white chocolate and the soybean lecithin, but its bioavailability has only improved 1.2~1.8 times at the most, and is very little to the influence of active component effect.
WO 97/44014 discloses a kind of solid dispersion of itraconazole, this solid dispersion has the influence of high bioavailability and unable to take food thing, its preparation is by adopting fusion-extrusion molding with itraconazole with such as mixture heated to 245~265 of water-soluble polymers such as hydroxypropyl emthylcellulose ℃, so that fused itraconazole is dispersed in the unfused water-soluble polymer.Yet wherein have several problems: fusion method should carry out under up to 245~265 ℃ temperature, and fused itraconazole is difficult to be evenly dispersed in the polymer.In addition, unfused itraconazole is in vivo residual, thereby stripping or absorption in vivo had side effects.
Korean Patent communique No.2001-0098419 discloses a kind of method that realizes solid dispersion, be about in the mixture that insoluble itraconazole is dispersed in polyvinylpyrrolidone and a kind of absorption enhancer, thereby the crystal form medicine is made for the amorphism medicine, to significantly improve water solublity.Yet, its problem is that the disintegrate of solid dispersion does not take place for a long time, and the dissolution of itraconazole (dissolution rate) is low, and this is because used excessive polyvinylpyrrolidone, even when in mimic gastric juice, solid preparation being carried out dissolution test, also be like this.
Therefore, needing a kind of insoluble drugs of exploitation is the higher Orally administered composition of bioavailability of itraconazole.
Summary of the invention
The present inventor finds, to permeate derivant, for example potassium chloride, magnesium carbonate etc., and disintegrating agent is when being added in the solid dispersion in the mixture that itraconazole wherein is scattered in hydroxypropyl emthylcellulose and absorption enhancer, the dissolving out capability of insoluble itraconazole can suitably be controlled and be significantly improved, thereby realizes the present invention.
Therefore, the object of the present invention is to provide a kind of Orally administered composition, described Orally administered composition contains solid dispersion, infiltration derivant and disintegrating agent, and wherein said solid dispersion is by preparing with amorphism in the mixture that itraconazole is dispersed in hydroxypropyl emthylcellulose and absorption enhancer.
Another object of the present invention is to provide a kind of preparation to contain the method for the Orally administered composition of itraconazole, the itraconazole of said composition has high bioavailability, described method comprises: itraconazole is dispersed in the mixture of hydroxypropyl emthylcellulose and absorption enhancer to prepare amorphous solid dispersion, then described solid dispersion is mixed mutually with infiltration derivant and disintegrating agent.
Another object of the present invention is to provide a kind of solid dispersion, and this solid dispersion is by in the mixture that itraconazole is dispersed in hydroxypropyl emthylcellulose and absorption enhancer and prepare with amorphism.
Description of drawings
It is the result of 1.2 o'clock dissolution test at pH that Fig. 1 shows the compositions that is made by the embodiment of the invention and Comparative Examples.
●: embodiment 2,
Zero: embodiment 3,
▲: Comparative Examples 1,
△: Comparative Examples 2.
Fig. 2 shows the result of the dissolution test of the compositions that made by the embodiment of the invention 2 and commercial preparation.
●: embodiment 2,
: the commercial preparation (Sporanox of Janssen Korea Ltd. TMCapsule).
Fig. 3 shows the result of the dissolution test of compositions when pH4.0 and pH6.8 that is made by the embodiment of the invention 2 and Comparative Examples 2.
▲: pH4.0+1% polysorbate80 (Polysorbate 80), the compositions of embodiment 2,
■: the pH4.0+1% polysorbate80, the compositions of Comparative Examples 2,
△: the pH6.8+1% polysorbate80, the compositions of embodiment 2,
: pH6.8+1% polysorbate80, the compositions of Comparative Examples 2.
The result of the dissolution test of solid dispersion (SDH) when pH1.2 and pH4.0 that Fig. 4 shows the solid dispersion (SDP) that contains polyvinylpyrrolidone and contains hydroxypropyl emthylcellulose.
▲:SPD-pH1.2,
△:SDH-pH1.2,
■:SDP-pH4.0,
□:SDH-pH4.0。
The specific embodiment
In conjunction with following detailed description, evaluation and the attendant advantages thereof more complete to the present invention will be more obvious along with the intensification of understanding.
The present invention relates to a kind of Orally administered composition, described compositions contains the solid dispersion of 40~69.9wt%, the infiltration derivant of 0.1~30wt% and the disintegrating agent of 0.1~30wt%, wherein, described solid dispersion is dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1~10 weight portion and 0.01~5 weight portion and prepares with amorphism.
In addition, the invention still further relates to the method that a kind of preparation contains the Orally administered composition of itraconazole, the itraconazole of said composition has high bioavailability, and described method comprises the steps:
The itraconazole of 1 weight portion is dispersed in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1~10 weight portion and 0.01~5 weight portion preparing amorphous solid dispersion,
The described solid dispersion of 40~69.9wt% is mixed mutually with the infiltration derivant of 0.1~30wt% and the disintegrating agent of 0.1~30wt%.
And, the invention still further relates to a kind of solid dispersion, this solid dispersion is dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1~10 weight portion and 0.01~5 weight portion and prepares with amorphism.
Korean Patent communique No.2001-0098419 discloses a kind of itraconazole preparation, and wherein the bioavailability of this itraconazole preparation is improved by itraconazole is made for amorphism.Yet, there is a problem like this, when itraconazole preparation during with solid dispersion form oral administration, active component, be the stripping meeting time-delay of itraconazole in simulated gastric fluid, this is because used excessive water-soluble polymer polyvinylpyrrolidone when the preparation solid dispersion.
For solving the problem of above-mentioned itraconazole stripping time-delay in gastric environment, in the present invention, water-soluble polymer is adopted in the preparation of itraconazole solid dispersion, it is hydroxypropyl emthylcellulose, and absorption enhancer, citric acid for example, thus in the solution that contains simulated gastric fluid and 1% (w/w) polysorbate80 of pH1.2 and pH4.0, dissolution has been significantly improved more than 20%.And in the present invention, also the solid dispersion to itraconazole adds the infiltration derivant, as potassium chloride, magnesium carbonate etc., and disintegrating agent, as microcrystalline Cellulose, sodium starch glycollate etc., so that the effectively stripping in gastric environment of insoluble itraconazole.
In the present invention, the itraconazole solid dispersion can be dispersed in by the itraconazole with 1 weight portion in the absorption enhancer mixture of the hydroxypropyl emthylcellulose of 0.1~10 weight portion and 0.01~5 weight portion and make with amorphism.The content of itraconazole solid dispersion is preferably 40~69.9wt%, in the gross weight of Orally administered composition.If the content of itraconazole solid dispersion less than 40wt%, will be not enough to obtain required drug effect; And if the content of itraconazole solid dispersion will have side effects to effective stripping of itraconazole greater than 69.9wt%.
In the present invention, absorption enhancer can be selected from one or more in citric acid, ascorbic acid, bile acid, cholic acid, mannitol, salicylic acid, glucose, dextrose, sucrose, sorbitol and the maltose.
In the present invention, the infiltration derivant can be selected from one or more in sodium chloride, potassium chloride, magnesium chloride, potassium sulfate, sodium sulfate, magnesium sulfate, magnesium carbonate, calcium bicarbonate, mannitol, glucose, lactose and the sucrose.The content of infiltration derivant is preferably 0.1~30wt%, in the gross weight of Orally administered composition.If the content of infiltration derivant is less than 0.1wt%, the then itraconazole stripping of will delaying time; If the content of infiltration derivant is greater than 30wt%, then the stripping of itraconazole improves fast, causes side effect, for example skin allergy etc.
In the present invention, disintegrating agent can be selected from one or more in microcrystalline Cellulose, low hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose (croscamellose sodium), sodium starch glycollate, sodium carboxymethyl cellulose, carboxymethyl cellulose and the crospolyvinylpyrrolidone (crospovidone) that replaces.The content of disintegrating agent is preferably 0.1~30wt%, in the gross weight of Orally administered composition.If the content of disintegrating agent is less than 0.1wt%, disintegrate will be delayed time; If the content of disintegrating agent is greater than 30wt%, solid preparation will to have flowability and compressibility difference etc. former thereby be difficult to preparation owing to granule.
In addition, Orally administered composition of the present invention also can comprise and is selected from pharmaceutically acceptable excipient, binding agent and the lubricant one or more.
In the present invention, excipient can be selected from one or more in lactose, white sugar, glucose, fructose, mannitol, corn starch, potato starch, wheaten starch, pre-gelatinized starch, microcrystalline Cellulose or cellulose derivative, dextrin, calcium hydrogen phosphate, dalcium biphosphate, calcium carbonate, polacrilin potassium, acetic acid, ammonium carbonate, ammonium phosphate, boric acid, lactic acid, citric acid, potassium phosphate, sodium phosphate, sodium acetate, sodium citrate, sodium lactate, ascorbic acid and the ascorbic palmitate.The content of excipient is preferably 2~90wt%, in the gross weight of Orally administered composition.
In the present invention, binding agent can be selected from one or more in hydroxypropyl cellulose, hydroxypropyl emthylcellulose, hydroxylated cellulose, methylcellulose, ethyl cellulose, hydroxyethyl-cellulose, polyvinylpyrrolidone, polyvinyl alcohol, gelatin, dextrin and the microcrystalline Cellulose.The content of binding agent is preferably 2~40wt%, in the gross weight of Orally administered composition.
In the present invention, lubricant can be selected from one or more in magnesium stearate, sodium stearyl fumarate, stearic acid, Talcum, silicon dioxide and the colloidal silica.The content of lubricant is preferably 0.1~20wt%, in the gross weight of Orally administered composition.
Orally administered composition of the present invention can preferably be made the solid that is used for oral administration, for example tablet, capsule, granule, powder, pill, dry syrup or the like, preferred tablet or capsule.
Orally administered composition of the present invention can be made into and contains 100~400mg, the unit dosage forms of preferred 150~300mg itraconazole solid dispersion.Dosage unit is preferably tablet or capsular form.In one week of administration, Orally administered composition of the present invention is administered twice preferred every day, each 200mg itraconazole.
As shown in Figure 4, use the itraconazole solid dispersion of water-soluble polymer hydroxypropyl emthylcellulose and absorption enhancer citric acid preparation to show higher dissolution in the solution of pH1.2 that contains simulated gastric fluid and 1% (w/w) polysorbate80 and pH4.0, this speed is than dissolution height at least 20% disclosed according to Korean Patent communique No.2001-0098419, that adopt the itraconazole solid dispersion of water-soluble polymer polyvinylpyrrolidone preparation.And, Orally administered composition of the present invention except that contain the itraconazole solid dispersion external, also contain the infiltration derivant, for example potassium chloride, magnesium carbonate etc., and disintegrating agent, for example microcrystalline Cellulose, sodium starch glycollate etc., thus show the effective stripping of insoluble itraconazole in gastric environment.
Further the present invention will be described in more detail in conjunction with following embodiment.These embodiment only are intended to the present invention exemplarily is described, and should not be construed as by any way the scope of the invention are limited.
Embodiment 1
One hectogram raw material itraconazole preparation (Sigma Chemical) is dissolved in 1, in the 000g dichloromethane.Then, 22.2g fully is dissolved in 2 as the citric acid and the 100g hydroxypropyl emthylcellulose (Dow Chemical, weight average molecular weight is 10,000~1,500,000) of absorption enhancer, (1:1 is v/v) in the mixed solvent for 000g dichloromethane/ethanol.Adopt spray dryer (B-191 mini spray exsiccator, Buchi Co., Switzerland) mixture solution of itraconazole solution and hydroxypropyl emthylcellulose and citric acid is sprayed, be scattered in solid dispersion in hydroxypropyl emthylcellulose and the citric acid to form itraconazole, generate white amorphous powder.Itraconazole: hydroxypropyl emthylcellulose: the weight ratio of citric acid is 45:45:10.
Embodiment 2
The itraconazole solid dispersion that embodiment 1 is made also fully mixes by the screening of 30 purpose mesh screens with colloidal silica.Then, other component in wherein adding tabulation 1 down except that magnesium stearate and Talcum is mixed, and dry and pelletize is crossed 25 order mesh screens and obtained the size homogeneous granules.Subsequently, to wherein adding magnesium stearate and Talcum and fully mixing, mixture is made tablet.120g Opadry AMB (Opadry AMB) (Colorcon) is added in the 546g pure water, fully mix with the preparation coating solution.Adopt tablet coating machine (the automatic coating machine of SFC-30FN type, Sejong Pharmatech, Korea S), keeping inlet temperature is 60~70 ℃, outlet temperature is 40~43 ℃, and coating solution is filmed on the tablet that makes, and wherein every tablet scribbles the coating solution of 20mg.
[table 1]
The itraconazole solid dispersion 222.2mg
Microcrystalline Cellulose 58.0mg
The dehydration lactose 143.0mg
Cross-linking sodium carboxymethyl cellulose 120.0mg
Magnesium carbonate 20.0mg
Colloidal silica 8.0mg
Talcum 7.0mg
Magnesium stearate 6.0mg
Embodiment 3
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 2 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 2]
The itraconazole solid dispersion 222.2mg
Microcrystalline Cellulose 58.0mg
The dehydration lactose 153.0mg
Cross-linking sodium carboxymethyl cellulose 120.0mg
Magnesium carbonate 10.0mg
Colloidal silica 8.0mg
Talcum 7.0mg
Magnesium stearate 6.0mg
Embodiment 4
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 3 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 3]
The itraconazole solid dispersion 222.2mg
Microcrystalline Cellulose 83.0mg
The dehydration lactose 123.0mg
Cross-linking sodium carboxymethyl cellulose 115.0mg
Magnesium chloride 20.0mg
Colloidal silica 8.0mg
Talcum 7.0mg
Magnesium stearate 6.0mg
Embodiment 5
Itraconazole solid dispersion and colloidal silica that embodiment 1 is made sieve by 30 order mesh screens, and fully mix.Then, other component in wherein adding tabulation 4 down except that magnesium stearate is mixed, and dry and pelletize is crossed 25 order mesh screens and obtained the size homogeneous granules.Subsequently, to wherein adding magnesium stearate and fully mixing with the preparation tablet.After tablet forms, by tablet being carried out coating as method identical among the embodiment 2.
[table 4]
The itraconazole solid dispersion 222.2mg
Microcrystalline Cellulose 80.0mg
The dehydration lactose 173.0mg
Cross-linking sodium carboxymethyl cellulose 75.0mg
Potassium chloride 20.0mg
Colloidal silica 8.0mg
Magnesium stearate 6.0mg
Embodiment 6
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 5 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 5]
The itraconazole solid dispersion 222.2mg
Microcrystalline Cellulose 70.0mg
The dehydration lactose 133.0mg
Cross-linking sodium carboxymethyl cellulose 135.0mg
Calcium bicarbonate 10.0mg
Colloidal silica 8.0mg
Magnesium stearate 6.0mg
Comparative Examples 1
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 6 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 6]
The itraconazole solid dispersion 222.2mg
Microcrystalline Cellulose 93.0mg
The dehydration lactose 158.0mg
Cross-linking sodium carboxymethyl cellulose 90.0mg
Colloidal silica 8.0mg
Talcum 7.0mg
Magnesium stearate 6.0mg
Comparative Examples 2
Component in itraconazole solid dispersion that employing embodiment 1 makes and the following tabulation 7 prepares tablet.Adopt and prepare tablet and it is carried out coating as method identical among the embodiment 2.
[table 7]
The itraconazole solid dispersion 222.2mg
Microcrystalline Cellulose 78.0mg
The dehydration lactose 143.0mg
Cross-linking sodium carboxymethyl cellulose 120.0mg
Colloidal silica 8.0mg
Talcum 7.0mg
Magnesium stearate 6.0mg
Comparative Examples 3
One hectogram raw material itraconazole preparation (Sigma Chemical) is dissolved in 1, in the 000g dichloromethane.Then, 22.2g fully is dissolved in 2 as the citric acid and the 200g polyvinylpyrrolidone (BASF, weight average molecular weight is 2,500~3,000,000) of absorption enhancer, (1:1 is v/v) in the mixed solvent for 000g dichloromethane/ethanol.Adopt spray dryer (B-191 mini spray exsiccator, Buchi Co., Switzerland) mixture solution of itraconazole solution and polyvinylpyrrolidone and citric acid is sprayed, be scattered in solid dispersion in polyvinylpyrrolidone and the citric acid to form itraconazole, generate white amorphous powder.Itraconazole: polyvinylpyrrolidone: the weight ratio of citric acid is 45:45:10.
Experimental example 1: dissolution test
Compositions and commercial preparation (Janssen Korea Ltd.Sporanox that embodiment 2~6 and Comparative Examples 1~2 are made TMCapsule) carries out dissolution test.The results are shown in down among tabulation 8 and Fig. 1 and 2.The solution (Korean Pharmacopeia) of pH1.2 as dissolution fluid, and is determined dissolution by the stripping quantity of the itraconazole that recorded by efficient liquid phase chromatographic analysis (HPLC).In this manual, dissolution is all measured according to above-mentioned identical mode.
[table 8]
Figure C200610065136D00121
As table 8 and shown in Figure 1, contain disintegrating agent in Comparative Examples 1 and 2 but do not contain in the compositions of permeating derivant, dissolution is significantly lower, and is difficult to control, because the slight change of each constituent content will cause the remarkable change of dissolution.And contain in the compositions of infiltration derivant and disintegrating agent at embodiment 2~6, dissolution significantly improves, and can (referring to Fig. 1) control dissolution in wide region.
In addition, as table 8 and shown in Figure 2, the compositions of the embodiment of the invention 2 also shows the dissolution equal or higher with the commercial preparation.
And below the experiment of carrying out will show that the present invention contains the compositions of permeating derivant and all have higher dissolution under pH4.0 and pH6.8 and pH1.2.Measure the dissolution that embodiment 2 (containing infiltration derivant and disintegrating agent) and Comparative Examples 2 contain (not containing the infiltration derivant) compositions of itraconazole respectively in the solution that contains 1% polysorbate80 of pH4.0 and in the solution that contains 1% polysorbate80 of pH6.8.The results are shown in Fig. 3.As shown in Figure 3, the present invention contains the compositions of infiltration derivant and disintegrating agent, and its dissolution all is higher than the compositions of Comparative Examples under pH4.0 and pH6.8.
In addition, for the kind of check water-soluble polymer to the influence of dissolution, respectively embodiment 1 is contained hydroxypropyl emthylcellulose and contains polyvinylpyrrolidone as the solid dispersion of water-soluble polymer and Comparative Examples 3 and carry out dissolution test as the solid dispersion of water-soluble polymer.Fill No. 0 capsule with the various solid dispersion of 222.2mg (corresponding to the 100g itraconazole), and in the solution that contains 1% (w/w) polysorbate80 of pH1.2 and pH4.0, each solid dispersion is carried out dissolution test respectively.The results are shown in following table 9 and Fig. 4.
[table 9]
Figure C200610065136D00131
As table 9 and shown in Figure 4, compare with the dissolution that Comparative Examples 3 contains in the solid dispersion of polyvinylpyrrolidone, contain in the solid dispersion of hydroxypropyl emthylcellulose at embodiment 1, dissolution improves at least 20% in the solution of pH1.2, and improves at least 60% in the solution of pH4.0.
As previously mentioned, in Orally administered composition of the present invention, can effectively control and significantly improve the dissolution in gastric environment, thereby solve the low problem of the insoluble bioavailability that causes by itraconazole.And Orally administered composition of the present invention also has economic benefit, because can directly prepare tablet by dry granulation by it.

Claims (4)

1. Orally administered composition, contain:
The solid dispersion of 40~69.9wt% wherein is dispersed in the itraconazole of 1 weight portion in the absorption enhancer of the hydroxypropyl emthylcellulose of 0.1~10 weight portion and 0.01~5 weight portion;
The infiltration derivant of 1~30wt%; And
The disintegrating agent of 1~30wt%,
Wherein said infiltration derivant is selected from one or more in sodium chloride, potassium chloride, magnesium chloride, potassium sulfate, sodium sulfate, magnesium sulfate, magnesium carbonate and the calcium bicarbonate, and described absorption enhancer is selected from citric acid, ascorbic acid, bile acid, mannitol, salicylic acid, glucose, dextrose, sucrose, sorbitol and maltose.
2. the Orally administered composition of claim 1, wherein said absorption enhancer is a cholic acid.
3. the Orally administered composition of claim 1, wherein said disintegrating agent are selected from one or more in microcrystalline Cellulose, low hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, sodium starch glycollate, sodium carboxymethyl cellulose, carboxymethylcellulose calcium and the crospolyvinylpyrrolidone that replaces.
4. the Orally administered composition of claim 1 further comprises in binding agent and the lubricant one or more.
CNB2006100651366A 2005-03-17 2006-03-17 Composition comprising itraconazole for oral administration Expired - Fee Related CN100479819C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020050022312A KR100555794B1 (en) 2005-03-17 2005-03-17 Composition comprising itraconazole for oral administration
KR1020050022312 2005-03-17

Publications (2)

Publication Number Publication Date
CN1853634A CN1853634A (en) 2006-11-01
CN100479819C true CN100479819C (en) 2009-04-22

Family

ID=37179259

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100651366A Expired - Fee Related CN100479819C (en) 2005-03-17 2006-03-17 Composition comprising itraconazole for oral administration

Country Status (3)

Country Link
KR (1) KR100555794B1 (en)
CN (1) CN100479819C (en)
HK (1) HK1098059A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101780046B (en) * 2009-01-16 2011-09-21 北京化工大学 Itraconazole composite powder and preparation method thereof
CN102309488A (en) * 2010-07-02 2012-01-11 北京京卫燕康药物研究所有限公司 Itraconazole medicinal composition and preparation method thereof
CN104055747A (en) * 2013-03-22 2014-09-24 四川滇虹医药开发有限公司 Itraconazole pharmaceutical composition, preparation method and application thereof
CN112641756B (en) * 2020-12-29 2022-08-19 卓和药业集团股份有限公司 Posaconazole enteric-coated pellet and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1398184A (en) * 1999-12-08 2003-02-19 东亚制药株式会社 Compsns. contg. itraconazole with improved bioavailability and narrow intra-and inter-individual variation of its absorption

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1398184A (en) * 1999-12-08 2003-02-19 东亚制药株式会社 Compsns. contg. itraconazole with improved bioavailability and narrow intra-and inter-individual variation of its absorption

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KR20010098419A(WPI摘要号:2002-251928【30】) 2001.11.08

Also Published As

Publication number Publication date
HK1098059A1 (en) 2007-07-13
CN1853634A (en) 2006-11-01
KR100555794B1 (en) 2006-03-03

Similar Documents

Publication Publication Date Title
AU2014233850B2 (en) Tofacitinib oral sustained release dosage forms
EP2663310B1 (en) Oral dosage forms for modified release comprising tasocitinib
NO176203B (en) Process for the preparation of delayed-release ibuprofen tablets
KR20000062327A (en) Immediately Disintegrable Medicinal Compositions
KR20100012867A (en) Solid dosage forms comprising tadalafil
KR100678421B1 (en) Controlled-release formulation containing tamsulosin hydrochloride
KR101977785B1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
EP4076402A1 (en) Dosage form comprising amorphous solid solution of empagliflozin with polymer
CN109152787A (en) Oral preparation with superior stripping property
CN109996542A (en) Oral disnitegration tablet comprising diamine derivative
KR100791844B1 (en) Sustained release formulations containing metformin or its salt and processes for preparing the same
EP1847257A2 (en) Solid preparation comprising enteric solid dispersion
JP2002326927A (en) Quick-releasing tablet containing metformin hydrochloride
CN100479819C (en) Composition comprising itraconazole for oral administration
JP2020518611A (en) Compositions with improved water solubility and bioavailability
WO2011039686A1 (en) Latrepirdine oral sustained release dosage forms
JP2022544167A (en) Pharmaceutical composition containing nitroxoline, nitroxoline oral solid tablet, method of preparation thereof, and use thereof
HU221590B (en) Retarded-action microtablet made of beta-phenylpropiophenone derivatives
CN105431140B (en) Compound formulation containing slow release of metformin and quick-release HMG-CoA reductase inhibitor
Parikh et al. Formulation optimization and evaluation of immediate release tablet of telmisartan
CN112168796B (en) Controlled-release drug sustained-release preparation of biphasic sustained-release system and preparation method thereof
KR102389339B1 (en) Controlled release high-dose tamsulosin hydrochloride tablet and its preparing method
KR101043816B1 (en) Controlled release formulation for oral administration of metformin and method
CN114831952A (en) Isosorbide mononitrate osmotic pump controlled release tablet and preparation method thereof
CN105407875A (en) Stable pharmaceutical composition in form of coated tablet comprising granules of isoniazid and granules of rifapentine against tuberculosis and process for preparing same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098059

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098059

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090422

Termination date: 20120317